Literature DB >> 33431856

Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry.

Jiwan Ge1, Ruoke Wang2, Bin Ju3, Qi Zhang2, Jing Sun4, Peng Chen2, Senyan Zhang1, Yuling Tian1, Sisi Shan2, Lin Cheng3, Bing Zhou3, Shuo Song3, Juanjuan Zhao3, Haiyan Wang3, Xuanling Shi2, Qiang Ding2, Lei Liu3, Jincun Zhao4, Zheng Zhang5, Xinquan Wang6, Linqi Zhang7.   

Abstract

Understanding the mechanism for antibody neutralization of SARS-CoV-2 is critical for the development of effective therapeutics and vaccines. We recently isolated a large number of monoclonal antibodies from SARS-CoV-2 infected individuals. Here we select the top three most potent yet variable neutralizing antibodies for in-depth structural and functional analyses. Crystal structural comparisons reveal differences in the angles of approach to the receptor binding domain (RBD), the size of the buried surface areas, and the key binding residues on the RBD of the viral spike glycoprotein. One antibody, P2C-1F11, most closely mimics binding of receptor ACE2, displays the most potent neutralizing activity in vitro and conferred strong protection against SARS-CoV-2 infection in Ad5-hACE2-sensitized mice. It also occupies the largest binding surface and demonstrates the highest binding affinity to RBD. More interestingly, P2C-1F11 triggers rapid and extensive shedding of S1 from the cell-surface expressed spike glycoprotein, with only minimal such effect by the remaining two antibodies. These results offer a structural and functional basis for potent neutralization via disruption of the very first and critical steps for SARS-CoV-2 cell entry.

Entities:  

Year:  2021        PMID: 33431856     DOI: 10.1038/s41467-020-20501-9

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  1 in total

1.  PyMod 2.0: improvements in protein sequence-structure analysis and homology modeling within PyMOL.

Authors:  Giacomo Janson; Chengxin Zhang; Maria Giulia Prado; Alessandro Paiardini
Journal:  Bioinformatics       Date:  2017-02-01       Impact factor: 6.937

  1 in total
  45 in total

Review 1.  Interactions of renin-angiotensin system and COVID-19: the importance of daily rhythms in ACE2, ADAM17 and TMPRSS2 expression.

Authors:  J Zlacká; K Stebelová; M Zeman; I Herichová
Journal:  Physiol Res       Date:  2021-12-16       Impact factor: 1.881

Review 2.  The humoral response and antibodies against SARS-CoV-2 infection.

Authors:  Hai Qi; Linqi Zhang; Bo Liu; Xinquan Wang
Journal:  Nat Immunol       Date:  2022-06-27       Impact factor: 31.250

3.  Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2.

Authors:  Xiaoyu Sun; Chunyan Yi; Yuanfei Zhu; Longfei Ding; Shuai Xia; Xingchen Chen; Mu Liu; Chenjian Gu; Xiao Lu; Yadong Fu; Shuangfeng Chen; Tianlong Zhang; Yaguang Zhang; Zhuo Yang; Liyan Ma; Wangpeng Gu; Gaowei Hu; Shujuan Du; Renhong Yan; Weihui Fu; Songhua Yuan; Chenli Qiu; Chen Zhao; Xiaoyan Zhang; Yonghui He; Aidong Qu; Xu Zhou; Xiuling Li; Gary Wong; Qiang Deng; Qiang Zhou; Hongzhou Lu; Zhiyang Ling; Jianping Ding; Lu Lu; Jianqing Xu; Youhua Xie; Bing Sun
Journal:  Nat Microbiol       Date:  2022-06-30       Impact factor: 30.964

4.  Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages.

Authors:  Xiaoman Li; Yongbing Pan; Qiangling Yin; Zejun Wang; Sisi Shan; Laixing Zhang; Jinfang Yu; Yuanyuan Qu; Lina Sun; Fang Gui; Jia Lu; Zhaofei Jing; Wei Wu; Tao Huang; Xuanling Shi; Jiandong Li; Xinguo Li; Dexin Li; Shiwen Wang; Maojun Yang; Linqi Zhang; Kai Duan; Mifang Liang; Xiaoming Yang; Xinquan Wang
Journal:  Cell Discov       Date:  2022-09-08       Impact factor: 38.079

Review 5.  Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants.

Authors:  Cong Sun; Chu Xie; Guo-Long Bu; Lan-Yi Zhong; Mu-Sheng Zeng
Journal:  Signal Transduct Target Ther       Date:  2022-06-28

6.  Mutational analysis of SARS-CoV-2 variants of concern reveals key tradeoffs between receptor affinity and antibody escape.

Authors:  Emily K Makowski; John S Schardt; Matthew D Smith; Peter M Tessier
Journal:  PLoS Comput Biol       Date:  2022-05-31       Impact factor: 4.779

Review 7.  Current Strategies of Antiviral Drug Discovery for COVID-19.

Authors:  Miao Mei; Xu Tan
Journal:  Front Mol Biosci       Date:  2021-05-13

8.  Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants.

Authors:  Jianhui Nie; Jingshu Xie; Shuo Liu; Jiajing Wu; Chuan Liu; Jianhui Li; Yacui Liu; Meiyu Wang; Huizhen Zhao; Yabo Zhang; Jiawei Yao; Lei Chen; Yuelei Shen; Yi Yang; Hong-Wei Wang; Youchun Wang; Weijin Huang
Journal:  Cell Discov       Date:  2021-07-20       Impact factor: 10.849

9.  Aggregation of high-frequency RBD mutations of SARS-CoV-2 with three VOCs did not cause significant antigenic drift.

Authors:  Tao Li; Zhimin Cui; Yunfei Jia; Ziteng Liang; Jianhui Nie; Li Zhang; Meng Wang; Qianqian Li; Jiajing Wu; Nan Xu; Shuo Liu; Xueli Li; Yimeng An; Pu Han; Mengyi Zhang; Yuhua Li; Xiaowang Qu; Qihui Wang; Weijin Huang; Youchun Wang
Journal:  J Med Virol       Date:  2022-01-28       Impact factor: 20.693

10.  A non-RBM targeted RBD specific antibody neutralizes SARS-CoV-2 inducing S1 shedding.

Authors:  Yingyi Long; Shuyi Song; Feiyang Luo; Xiaojian Han; Chao Hu; Yingming Wang; Shenglong Li; Wang Wang; Huajun Zhang; Bo Zhang; Tingting Li; Aishun Jin
Journal:  Biochem Biophys Res Commun       Date:  2021-07-20       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.